Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Non-randomized, Two-treatment, Single-period, Single Dose, Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL® 100 mg Film-coated Tablets (Dasatinib) in Adult Human Subjects

Next Previous
Trial Profile

Open-label, Non-randomized, Two-treatment, Single-period, Single Dose, Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL® 100 mg Film-coated Tablets (Dasatinib) in Adult Human Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Omeprazole (Primary)
  • Indications Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Glioblastoma; Malignant-mesothelioma; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Sarcoma; Solid tumours; Waldenstrom's macroglobulinaemia
  • Focus Pharmacokinetics
  • Sponsors Xspray Pharma

Most Recent Events

  • 04 Jun 2024 Results investigated proton pump inhibitor (PPI) and TKI comedication and influence of timing of PPI comedication on the absorption and bioavailability of dasatinib , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 28 Nov 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top